These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 27684412)

  • 21. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Mosca L; Ballantyne CM; Bays HE; Guyton JR; Philip S; Doyle RT; Juliano RA
    Am J Cardiol; 2017 Feb; 119(3):397-403. PubMed ID: 27939227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
    Singh S; Arora RR; Singh M; Khosla S
    Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
    J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of omega-3 Fatty Acid therapies.
    Bradberry JC; Hilleman DE
    P T; 2013 Nov; 38(11):681-91. PubMed ID: 24391388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus.
    Tajuddin N; Shaikh A; Hassan A
    Diabetes Metab Syndr Obes; 2016; 9():109-18. PubMed ID: 27143943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.
    Barter P; Ginsberg HN
    Am J Cardiol; 2008 Oct; 102(8):1040-5. PubMed ID: 18929706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Preston Mason R
    Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
    Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
    Mosca L; Navar AM; Wenger NK
    J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Braeckman RA; Philip S; Stirtan WG; Doyle RT; Soni PN; Juliano RA
    J Clin Lipidol; 2016; 10(3):635-645.e1. PubMed ID: 27206952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
    J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
    Ballantyne CM; Braeckman RA; Bays HE; Kastelein JJ; Otvos JD; Stirtan WG; Doyle RT; Soni PN; Juliano RA
    J Clin Lipidol; 2015; 9(3):377-83. PubMed ID: 26073397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
    Trivedi K; Le V; Nelson JR
    Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.
    Bays HE; McKenney J; Maki KC; Doyle RT; Carter RN; Stein E
    Mayo Clin Proc; 2010 Feb; 85(2):122-8. PubMed ID: 20118387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
    Dogay Us G; Mushtaq S
    Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Nelson JR; True WS; Le V; Mason RP
    Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.